Activation of A 3 adenosine receptors (A 3 ARs) rapidly enhances the activity of antidepressant-sensitive serotonin (5-HT) transporters (SERTs) in vitro, ex vivo, and in vivo. A 3 AR agonist stimulation of SERT activity is lost in A 3 AR knockout mice. A 3 AR-stimulated SERT activity is mediated by protein kinase G1 (PKGI)-and p38 mitogen-activated protein kinase (MAPK)-linked pathways that support, respectively, enhanced SERT surface expression and catalytic activation. The mechanisms by which A 3 ARs target SERTs among other potential effectors is unknown. Here we present evidence that A 3 ARs are coexpressed with SERT in midbrain serotonergic neurons and form a physical complex in A 3 AR/hSERT cotransfected cells. Treatment of A 3 AR/SERT-cotransfected Chinese hamster ovary cells with the A 3 AR agonist N 6 -(3-iodobenzyl)-N-methyl-5Ј-carbamoyladenosine (1 M, 10 min), conditions previously reported to increase SERT surface expression and 5-HT uptake activity, enhanced the abundance of A 3 AR/SERT complexes in a PKGIdependent manner. Cotransfection of SERT with L90V-A 3 AR, a hyperfunctional coding variant identified in subjects with autism spectrum disorder, resulted in a prolonged recovery of receptor/transporter complexes after A 3 AR activation. Because PKGI and nitric-oxide synthetase are required for A 3 AR stimulation of SERT activity, and proteins PKGI and NOS both form complexes with SERT, our findings suggest a mechanism by which signaling pathways coordinating A 3 AR signaling to SERT can be spatially restricted and regulated, as well as compromised by neuropsychiatric disorders.
Introduction
The presynaptic, antidepressant-sensitive 5-HT transporter (SERT, SLC6A4) is predominantly responsible for high-affinity 5-HT clearance in the nervous system (Fuller, 1994) and also contributes to 5-HT homeostasis and signaling in non-neuronal tissues, including platelets, gut, adrenal gland, and placenta (Blakely, 2001; Gershon, 2004; Mercado and Kilic, 2010) . Numerous studies have found that a common polymorphism in the SERT promoter (i.e., the serotonintransporter-linked polymorphic region) is associated with altered behavioral traits, brain function, and risk for neuropsychiatric disorders (Homberg and Lesch, 2011) . Six rare SERT coding variants have been identified in subjects with obsessive-compulsive disorder (OCD) and autism; re-markably, each confers elevated constitutive activity of SERT in transfected cells as well as in lymphoblastoid lines derived from affected subjects (Prasad et al., 2005 ). Because only a small number of patients with OCD or autism carry the aforementioned SERT coding variants, we have sought to define mechanisms of broader relevance by which SERT expression or activity are augmented, with the intention of identifying additional contributors to 5-HT linked risk determinants of mental illness.
Multiple signaling pathways seem to contribute to the regulation of SERT-mediated 5-HT clearance . With respect to SERT stimulation, G-protein coupled receptor (GPCR) stimulation can activate protein kinase GI (PKGI)-linked pathways that rapidly up-regulate SERT activity via increased SERT surface expression (Steiner et al., 2008) and via a p38 mitogen-activated protein kinase (MAPK)-linked pathway that induces a catalytic activation of SERT (Zhu et al., 2004 . This latter pathway can be independently activated through stimulation of proinflammatory cytokine receptors Zhu et al., 2006 Zhu et al., , 2007 . Activation of A 3 subtype adenosine receptors (A 3 AR) can increase 5-HT uptake via PKG-linked pathways in peripherally derived cells (Miller and Hoffman, 1994; Zhu et al., 2004) . In the CNS (Okada et al., 1999) , in vivo microdialysis studies demonstrated A 3 AR-dependent reductions of extracellular 5-HT in hippocampus, an effect consistent with our studies that demonstrate A 3 AR-dependent stimulation of hippocampal 5-HT clearance (Zhu et al., 2007) .We have demonstrated that pharmacologically mediated A 3 AR modulation of SERT is lost in A 3 AR KO mice, confirming the specificity of the pathways targeted by pharmacological agents with reported A 3 AR specificity (Gallo-Rodriguez et al., 1994) . In addition to PKGI-dependent A 3 AR activation of SERT, we have demonstrated that activation of p38 MAPK enhances SERT catalytic activity (Zhu et al., 2004 (Zhu et al., , 2006 . Together, a full appreciation of the mechanisms by which activation of A 3 ARs control trafficking and catalytic activation of SERT proteins requires an understanding of whether regulation is indirect or is mediated by more confined, physical interactions. To date, compartmentalizing mechanisms by which GPCRs can target one or more of these modulators to regulate SERT without influencing other cytosolic and membrane effectors are unknown. Here, we provide evidence that A 3 ARs also exist within SERT complexes, suggesting a highly compartmentalized SERT "regulome." Moreover, we find that A 3 AR agonists can regulate the abundance of SERT/A 3 AR complexes in a PKGI-dependent manner.
Materials and Methods

Reagents. N
6
-(3-iodobenzyl)-N-methyl-5Ј-carbamoyladenosine (IB-MECA) was purchased from Sigma-Aldrich (St. Louis, MO); DT-2 was a kind gift from Dr. Wolfgang Dostmann (University of Vermont, Burlington, VT) (Dostmann et al., 2000) . Anti-HA-affinity matrix was purchased from Roche (South San Francisco, CA), and anti-myc resin, Streptavidin-coated agarose beads, and EZ-Link sulfosuccinimidyl 2-(biotinamido)-ethyl-1,3-dithiopropionate were obtained from Thermo Fisher Scientific (Waltham, MA). Trypsin-EDTA, glutamine, and ampicillin/streptomycin were purchased from Invitrogen (Carlsbad, CA); components of modified Eagle's medium and Dulbecco's modified Eagle's medium were obtained from Invitrogen and prepared in the Vanderbilt Media Core. Human SERT-specific mouse monoclonal antibody (ST51-2) was obtained from MAb Technologies (Atlanta, GA). Rodent-specific, goat anti-SERT polyclonal antibody was obtained from Frontier Science (Hokkaido, Japan). Anti-5-HT and anti-A 3 AR antibodies were products of Immunostar (Hudson, WI) and Alomone Labs Ltd. (Jerusalem, Israel), respectively. Secondary antibodies for immunostaining and immunoblotting were obtained from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA). All other biochemical reagents were of the highest grade possible and obtained from Sigma (St Louis, MO).
Immunohistochemistry Studies. All studies involving mice were conducted under the auspices of an approved protocol of the Vanderbilt University Institutional Animal Care Use Committee. C57BL/6 mice used for immunocytochemistry studies were purchased from Harlan, Inc., (Indianapolis, IN) and housed in Vanderbilt University animal housing facilities, with water and food provided ad libitum. For perfusion-fixation, mice were anesthetized using injection of 100 mg/kg i.p. pentobarbital (Nembutal) and then transcardially perfused with ice-cold 0.1 M PBS, pH 7.4. Fifty milliliters of ice-cold 4% paraformaldehyde in 0.1 M PBS, pH 7.4, was then perfused at a rate of 4 ml/min. Subsequently, brains were removed and fixed in paraformaldehyde buffered overnight at 4°C, followed by another overnight incubation in 30% sucrose in PBS before sectioning. Free-floating, frozen microtome sections (40 m) were preblocked in 3% normal donkey serum (Jackson ImmunoResearch Laboratories), 0.2% Triton X-100 in PBS for 1 h at room temperature. Primary antibodies targeting A 3 ARs (1:100), 5-HT (1: 800), or SERT (1:1000) were then applied to sections overnight at 4°C. After washing in PBS, sections were incubated with secondary antibodies (Dylight 488 donkey anti-rabbit IgG for A 3 ARs, 1:200; Dylight 549 donkey anti-goat IgG for 5-HT and SERT, 1:200; both from Thermo Fisher Scientific) for 2 h at room temperature. After multiple PBS washes, sections were mounted with Aqua-Poly/Mount (Polysciences, Inc., Warrington, PA). Immunofluorescence was captured using a Zeiss LSM 510 confocal microscope (Vanderbilt University Medical Center Cell Imaging Shared Resource).
Recovery of SERT/A 3 AR Complexes from Receptor/Transporter Transfected Cells. Chinese hamster ovary (CHO) cells (American Type Culture Collection, Manassas, VA) were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 1% L-Glu, and penicillin/streptomycin (100 units ⅐ g Ϫ1 ⅐ ml Ϫ1 ). Transfections were performed using Trans-It reagent (Mirus, Madison, WI). SERT (HA-tagged or nontagged) cDNA and/or A 3 AR cDNA (myc-or HA-tagged) were preincubated with transfection reagent per manufacturer's recommendations at ambient temperature for 30 min before adding to plated cells. Typically, 1 g of SERT construct and/or 0.5 to 1 g of A 3 AR constructs were added to each well of a six-well plate seeded with 5 ϫ 10 5 cells 24 h earlier. Cells were cultured for 24 to 48 h before biotinylation or generation of detergent extracts for coimmunoprecipitation (coIP) experiments. In some experiments, transfected cells were treated with IB-MECA Ϯ DT-2 for 10 to 40 min at 37°C before harvest. For coIP experiments, cells were lysed with 1% ice-cold Triton X-100 in PBS buffer containing protease inhibitors and 10 mM n-ethylmaleimide. Cell lysates were centrifuged at 20,000g for 20 min. In samples cotransfected with HA-SERT/myc-A 3 AR, 30 l of anti-HA antibody-coated resin or 10 l of anti-myc antibody-coated resin was used to extract protein complexes. Affinity resins (30 l) were added to cell extracts (0.4 ml) and incubated overnight at 4°C. Subsequently, beads were washed three times with ice-cold lysis buffer and bound proteins were eluted with 50 l of Laemmli buffer (62.5 mM Tris, pH 6.8, 20% glycerol, 2% SDS, 5% ␤-mercaptoethanol, and 0.01% bromphenol blue), separated by SDS-polyacrylamide gel electrophoresis, and transferred to polyvinylidene difluoride membrane (Millipore, Bedford, MA) preblocked with 5% nonfat dry milk in PBS/0.1% Triton X-100. Blots were incubated with either anti-myc antibodies (1:500; for HA-resin-incubated samples), anti-HA, or anti-SERT antibodies (1:500; for mycresin-incubated samples). Bound antibody was detected with horseradish peroxidase-conjugated, goat anti-mouse secondary antibody, or mouse anti-rabbit secondary antibody (1:10,000; both were from Serotonin Transporters Associate with A 3 Adenosine Receptors Jackson ImmunoResearch Laboratories). Horseradish peroxidase signals were developed with ECL-Plus reagents according to manufacturer's recommendations (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK).
Analysis of SERT Surface Expression. For biotinylation studies, cells were washed twice with ice-cold PBS/CM, and incubated with 1 ml/well EZ-Link sulfosuccinimidyl 2-(biotinamido)-ethyl-1,3-dithiopropionate (1 mg/ml in PBS/CM; Thermo Fisher) for 30 min at 4°C. The biotinylation reagent was quenched by two PBS/CM washes, followed by 10 min incubation with 100 mM glycine in PBS/CM, and then an additional two washes with PBS/CM. Cells were then lysed in radioimmunoprecipitation assay buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton-X-100, and 1% sodium deoxycholic acid) containing protease inhibitors (1 M pepstatin A, 250 M phenylmethylsulfonyl fluoride, 1 g/ml leupeptin, and 1 g/ml aprotinin) for 30 min at 4°C with constant shaking. Lysates were centrifuged at 20,000g for 30 min at 4°C and then incubated with Streptavidin beads (30 l of beads/cell lysate per well) for 45 min at room temperature. Beads were washed three times with radioimmunoprecipitation assay buffer, and bound proteins were eluted with 30 l of Laemmli buffer for 1 h at room temperature. Samples were centrifuged for 10 min, and supernatants were analyzed by SDS-polyacrylamide gel electrophoresis (10%) as described above. To estimate the relative abundance of proteins in total and surface immunoblots, samples were exposed to Kodak X-ray film and scanned using an AGFA Duoscan T1200. Blots for intracellular proteins (e.g., actin) in this protocol do not reveal significant recovery in biotinylated fractions. Captured images were quantified using NIH Image software (http://rsbweb.nih.gov/nihimage/), using multiple exposures to insure data capture in the linear range of the film.
Statistical Analyses. All data derive from experiments replicated a minimum of three times. Statistical analyses were performed using Prism 4.0 (GraphPad Software, San Diego, CA) with a significance level set at P Ͻ 0.05 for all experiments. Specific analyses are given in the Figure legends.
Results
Coexpression of SERT and A 3 AR in Mouse Brain.
Little information exists regarding the regional distribution of A 3 ARs (Dixon et al., 1996; Yamano et al., 2007) , and there are no data relevant to A 3 ARs within serotonergic neurons. Initially, we performed reverse transcription-PCR analysis of midbrain RNA and could readily detect an amplification product matching that expected for A 3 ARs (B. Thompson, personal communication). To gain cellular resolution of A 3 AR protein in the mouse midbrain, we probed sections from C57BL/6 mice using a recently developed A 3 AR antibody (Alomone Labs Ltd), alone or in combination with antibodies targeting 5-HT or SERT. As shown in Fig. 1 , A to C, A 3 AR labeling was evident in serotonergic dorsal raphe neurons as revealed by colabeling of receptor expressing cells with 5-HT. SERT immunoreactivity is enriched in serotonergic axons and could be colocalized with A 3 AR immunoreactivity (Fig. 1,  D-F) , although other sites of A 3 AR expression were also evident, consistent with evidence that A 3 ARs are also expressed by glutamatergic neurons (Macek et al., 1998) . It is noteworthy that incubations of sections without primary antibodies or with the peptide constituting the A 3 AR epitope failed to demonstrate either cell body or fiber labeling (Supplemental Fig. 1 ). Finally, sections costained A 3 AR and glutamic acid decarboxylase (GAD) as a marker of raphe GABAergic terminals on 5-HT neurons (Fig. 1, G-I ) failed to demonstrate colabeling.
Physical Association of SERT with A 3 AR in Transfected CHO Cells. Efforts to perform coimmunoprecipitation of SERT and A 3 AR from midbrain extracts were unsuccessful (as is Western blotting of A 3 ARs), probably as a result of the insensitivity of our A 3 AR antibody. Use of other commercial A 3 AR antibodies was similarly unsuccessful. Thus, to assess SERT/A 3 AR associations, we turned to epitope-tagged transporter/receptor-transfected CHO cells, a model system that supports regulation of SERT activity by transfected A 3 ARs (Zhu et al., 2004) . HA-tagged SERT (HA-SERT) and myc-tagged A 3 AR (myc-A 3 ) cDNAs were individually or cotransfected and then immunoprecipitated and blotted from detergent extracts as described under Materials and Methods. As shown in Fig. 2, A and B, SERT immunoprecipitates were found to include A 3 ARs. A 3 ARs were not recovered from extracts of cells transfected with A 3 AR cDNA but lacking HA-SERT. Detergent extracts of separately transfected cells that were mixed after membrane solubilization also did not support recovery of A 3 AR proteins with SERT-directed antibodies. These findings are consistent with an endogenous formation of receptor/transporter complexes, as opposed to an artifactual association arising during extraction. Similar results ( Fig. 2C-D) were obtained when we reversed the targets for immunoprecipitation and immunoblotting (IP anti-myc (A 3 AR), blot anti-HA (SERT)) or used nontagged SERT in transfections (data not shown).
A 3 AR Agonist IB-MECA Enhances Recovery of SERT Complexes in a PKGI-Dependent Manner. To examine whether A 3 AR/SERT complexes are constitutive or subject to regulation, we treated receptor/transporter-transfected CHO Gallo-Rodriguez et al., 1994) . We used a concentration of IB-MECA (1 M) shown previously to rapidly enhance SERT activity (Zhu et al., 2007) . Anti-HA (SERT) immunoprecipitates of nonstimulated cells (Fig. 3A) contained readily detectible myclabeled A 3 ARs as noted above. IB-MECA treatment of cells for 10 min induced an enhanced recovery of A 3 AR/SERT complexes that was time-dependent and blocked by pretreatment with 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(Ϯ)-dihydropyridine-3,5-dicarboxylate (MRS1191; 1 M), a specific A 3 AR antagonist (Figs. 3, A and B, and 4, A  and B) . Total A 3 AR levels were unchanged by agonist or antagonist treatments. A similar elevation of A 3 AR/SERT complexes after IB-MECA treatments was detected when the coimmunoprecipitation paradigm was reversed to isolate A 3 AR complexes, blotting for HA-SERT (Fig. 3, C and D) .
To determine whether the effects of IB-MECA derive from the PKGI-linked signaling pathway, we conducted IB-MECA treatment of receptor/transporter cotransfected cells in the presence of PKGI-specific antagonist DT-2 (Dostmann et al., 2000) . In initial experiments, we found that DT-2 at concentrations at or below 0.3 M failed to alter recovery of basal SERT/A 3 AR complexes (data not shown). However, DT-2 (0.1 M) significantly attenuated the stimulatory effect of IB-MECA on the level of receptor/transporter complexes in coimmunoprecipitations (Fig. 3C-D) .
Transient and PKGI-Dependent Elevations in SERT Surface Expression by IB-MECA Stimulation of A 3 AR/ SERT Cotransfected Cells. Our previous work demonstrated that activation of A 3 AR can induce a PKG-dependent increase in surface expression of SERT (Zhu et al., 2004) . To determine whether IB-MECA-induced increase in recovery of A 3 AR/SERT complexes correlates temporally with elevated SERT surface levels, we conducted biotinylation experiments, blotting total and cell surface fractions for SERT immunoreactivity. As seen in previous studies of transiently (Zhu et al., 2004) , we observed an elevation of surface SERT (but not total SERT) with 10 min of stimulation that returned to nonstimulated level by 40 min (Fig. 5,  A and B) . Pretreatment of cells with A 3 AR MRS1191 completely abolished IB-MECA-induced surface SERT elevation (Fig. 4, C and D) . Surface fractions blotted for SERT demonstrated the expected enrichment of heavily glycosylated 90-to 100-kDa protein, whereas total extracts were more enriched for less heavily glycosylated 50-to 60-kDa forms (Fig. 5A) . As with the PKGI dependence of IB-MECA elevations in A 3 AR/SERT complexes, IB-MECA increased surface SERT protein could be blocked by DT-2 (Fig. 5, C  and D) .
A 3 AR Variant L90V Found in Subjects with Autism Spectrum Disorder Enhances Recovery of A 3 AR Complexes and SERT Surface Expression. Multiple hyperactive SERT coding variants have been identified in subjects with ASD . Because these variants are rare, we have sought evidence for genetic variation in SERT modulatory genes that might also produce anomalous elevations of wild-type SERT (Campbell et al., 2009) . We identified an A 3 AR coding variant L90V in subjects with ASD that shows a more prolonged, agonist-dependent increase in both cGMP levels and SERT activity (N. Campbell, C.-B. Zhu, K. Lindler, R. Blakely, and J. Sutcliffe, manuscript in preparation). To examine the impact of the L90V-A 3 AR variant on basal and regulated SERT protein associations and surface expression, we cotransfected myc-A 3 AR or myc-L90V-A 3 AR with SERT and stimulated receptors with IB-MECA. In total extracts of coimmunoprecipitation experiments, we observed no impact of the L90V variant on A 3 AR receptor expression with or without IB-MECA exposure (Fig. 6A) . However, and consistent with effects on uptake, whereas IB-MECA enhanced recovery of wild-type and L90V A 3 AR/SERT complexes equally after 10 min of exposure, L90V-A 3 AR/SERT complexes remained significantly elevated above vehicle controls at 40 min of IB-MECA exposure, and by 40 min, wild-type A 3 AR/SERT complex levels returned to those seen vehicle treatments (Fig. 6A-B) . As with wild-type A 3 AR at 10 min, pretreatment of IB-MECA-treated cells with either MRS1191 or DT-2 abolished the effects of IB-MECA on L90V-A 3 AR-SERT associations at 40 min (Fig. 6, C and D) . Finally, the prolonged impact of the A 3 AR L90V variant on recovery of receptor/ transporter complexes was mirrored by a sustained effect of IB-MECA on SERT surface expression (Fig. 6, E and F) . 
Discussion
SERT activity is known to be regulated at both transcriptional and post-translational levels (Blakely et al., 1998; Bauman et al., 2000) with evidence derived from kinase/phosphatase inhibitors and activators on transfected cell lines (Ramamoorthy and Blakely, 1999) , cultured pulmonary endothelial and smooth muscle cells (Ren et al., 2011) , platelets (Carneiro and Blakely, 2006) , nerve terminal preparations (Zhu et al., 2007) , brain slices (Ansah et al., 2003) , as well as in the CNS in vivo (Daws and Toney, 2007) . In recent years, we have focused on receptors that regulate SERT via PKG and p38 MAPK signaling pathways (Zhu et al., 2004 (Zhu et al., , 2007 Blakely et al., 2005) . With respect to the current report, we demonstrated that in both RBL-2H3 and transiently transfected CHO cells, A 3 ARs have the capacity to rapidly regulate SERT trafficking and catalytic activity, respectively (Zhu et al., 2004) . In addition, Zhu et al. (2004) demonstrated that A 3 AR stimulation of SERT requires phospholipase C, Ca 2ϩ , NOS, guanylyl cyclase, and PKG. More recently, we identified PKG-dependent regulation of SERT by A 3 ARs in mouse CNS nerve terminal preparations (synaptosomes), regulation absent in synaptosomes prepared from A 3 AR knockout mice (Zhu et al., 2007) . Our current report provides evidence that A 3 ARs are expressed in midbrain serotonergic neurons, where they can be colocalized with SERT. Moreover, we provide evidence that A 3 ARs and SERT can form regulated, detergentresistant complexes in receptor/transporter cotransfected cells.
Although multiple physiological and behavioral studies point to A 3 AR-dependent actions of adenosine, evidence of A 3 AR localization in the CNS is limited. Indeed, some investigators have questioned whether the A 3 AR is expressed in the brain at all (Rivkees et al., 2000) , and the Allen Brain Atlas project (http://www.brain-map.org) detects little if any A 3 AR mRNA in brain by in situ hybridization. Zhou et al. (1992) originally cloned A 3 AR cDNA from rat striatal mRNA but in reverse transcription-PCR studies found only a low level expression of the receptor in cortex, striatum, and olfactory bulb, being more highly expressed in testis and lung. Salvatore et al. (2000) described somewhat higher levels of A 3 AR mRNA in whole-brain extracts by Northern analysis, though still much lower than in peripheral tissues. Yaar et al. (2002) found significant and discretely localized expression of ␤-galactosidase in the CNS of A 3 AR promoter reporter mice, although cautious interpretation of the distributions reported in these studies is warranted because of the small size of the promoter fragment used and the differing patterns evident in different reporter lines.
Using single-cell PCR, Lopes et al. (2003) identified A 3 AR mRNA in rat hippocampal neurons and by Western blot analysis also detected A 3 AR protein in nerve terminal membranes. These effects are consistent with our findings of A 3 AR immunoreactivity in nonserotonergic and non-GABAergic fibers in the dorsal raphe, possibly derived from descending glutamatergic inputs. In monitoring effects of caffeine on extracellular 5-HT levels in hippocampus in the presence of A1 and A2 subtype antagonists and the SSRI fluoxetine, Okada et al. (1999) were the first to suggest a role for A 3 ARs in presynaptic modulation of 5-HT reuptake. We have provided evidence that the A 3 AR agonist IB-MECA rapidly enhances 5-HT transport in mouse midbrain synaptosomes and enhance 5-HT clearance rates in vivo (Zhu et al., 2007) . Consistent with these findings, immunolabeling of mouse midbrain sections revealed A 3 AR immunoreactivity that colocalized with both 5-HT and SERT labeling of raphe cell bodies and fibers, respectively. Specificity of antisera is always important to document and even more so with the apparent low level expression of the A 3 AR, as seen with many CNS GPCRs. Although staining for all targets was absent with the omission of primary antibodies (Supplemental Fig. 1 ) and our A 3 AR antibody 
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detects human nontagged A 3 AR in transfected cells (data not shown), we were unable to document consistent loss of A 3 AR immunoreactivity using sections from A 3 AR knockout mice. The A 3 AR antibody targets the 3rd intracellular loop (from 216 to 230 amino acids; http://www.alomone.com) of A 3 AR, whereas the deletion of A 3 AR in A 3 AR knockouts targets the N-terminal half of the receptor [up to the third transmembrane domain (Salvatore et al., 2000) ], thus leaving the antibody recognition intact. In addition, the mouse and human A 3 ARs exhibit alternatively spliced mRNAs that encode a truncated protein and that preserve the C-terminal 179 amino acids of the receptor, including the epitope for our A 3 AR antibody. This alternatively spliced product of the A 3 AR gene seems to be widely expressed, including in the CNS (Burnett et al., 2010) . To better address A 3 AR specificity issues, we also coincubated our receptor antibodies with an A 3 AR peptide and found a complete absence of staining in cell bodies or fibers. In addition, we double-stained sections with antibodies to GAD, a marker of GABAergic nerve terminals and demonstrated a lack of overlap with A 3 AR staining. Together, these findings provide the best evidence achievable with current reagents that A 3 AR proteins are coexpressed with SERT in vivo.
To our knowledge, ours are the first studies to identify a complex between a GPCR and SERT. It is noteworthy that D2 subtype DA receptors have been found to associate with and regulate activity of DAT proteins (Lee et al., 2009) , suggesting that receptor/neurotransmitter transporter complexes may be a more general phenomenon. Whereas D2/ DAT receptor complexes seem to be insensitive to D2 agonist stimulation, the A3AR agonist IB-MECA can regulate A 3 AR/ SERT complexes in a PKGI-dependent manner. With respect to a signaling network triggered by A 3 ARs, PKGI␣ and SERT colocalize in transformed serotonergic cells line (RN46A) and physically associate in receptor/kinase cotransfected cells . DT-2 is a peptide inhibitor that shows a nearly 1000-fold selectivity for PKGI isoforms versus PKGII (12.5 nM versus 9.1 M) (Dostmann et al., 2000; Steiner et al., 2009) . Because activation of PKG produces an increase in SERT activity that is accompanied by elevated surface expression (Zhu et al., 2004 ; current study), we speculate that the formation or stabilization of A 3 AR/SERT complexes is an important facet of PKGI-dependent, 5-HT uptake enhancement. It is noteworthy that A 3 AR enhancement of SERT has been found to require NOS activity and neuronal NOS has been found to be associated with SERT in mouse brain (Chanrion et al., 2007) , suggesting that a large SERT regulatory complex assembles to achieve efficient A 3 AR-dependent modulation of the transporter. Studies that prevent PKGI-and NOS-dependent SERT/A 3 AR associations, likely using A 3 AR and/or SERT mutants that disrupt their interactions, are needed to determine the spatial and temporal control of SERT by the A 3 AR/NOS/PKGI pathway. We have reported previously that peripheral activation of the native immune system that induces an elevation in pro-inflammatory cytokines in both the periphery and brain rapidly elevates CNS SERT activity (Zhu et al., 2010) . This effect requires p38 MAPK activity, and A 3 AR stimulation of SERT also requires concurrent p38 MAK activation. Additional studies are needed therefore to assess whether components of both PKGI and p38 MAPK signaling pathways assemble with SERT and whether such complexes could be independently regulated.
With respect to molecular mechanisms that can facilitate assembly of an A 3 AR-linked signaling pathway with SERT, the LIM domain scaffolding protein Hic-5 is known to associate with platelet SERT. Hic-5 dissociates from internalized SERT after PKC activation (Carneiro and Blakely, 2006) . The fibrinogen receptor, integrin ␣IIb␤3, a structural and signaling component of focal adhesions, also associates with platelet SERT and enhances transporter surface expression . Other reported SERT-interacting proteins include PICK1, syntaxin 1A, SCAMP2, ␣-synuclein, Rab4, and vimentin (for review, see Mercado and Kilic, 2010) . We and others have demonstrated that PKGI␣ and the catalytic subunit of the Ser/Thr protein phosphatase 2A regulate SERT phosphorylation (Ramamoorthy and Blakely, 1999; Bauman et al., 2000; Zhang and Rudnick, 2011) and are physically associated with the transporter (Bauman et al., 2000; Steiner et al., 2009 ). Finally, neuronal NOS, an essential signaling molecule in A 3 AR-triggered PKGI and p38 MAPK-dependent activation (Zhu et al., 2004 ) is a SERTassociated protein (Chanrion et al., 2007) . In the context of evidence presented here that A 3 ARs interact with SERT, we propose that SERT trafficking, localization, and catalytic activation require assembly of a much larger and regulated macromolecular complex in which compromised interactions could affect risk for disorders associated with altered 5-HT signaling.
To explore the hypothesis that A 3 AR/SERT complexes could be influenced by disease-associated mechanisms, we seek to determine whether the A 3 AR coding variant L90V, recently identified in subjects with ASD (Campbell et al., manuscript in preparation) , could alter receptor modulation of SERT trafficking or its assembly into a receptor/ transporter complex. The L90V variant produces elevated basal cGMP levels in transfected cells compared with wild type A 3 AR, and upon IB-MECA stimulation, leads to a more sustained enhancement of cGMP production and 5-HT uptake (Campbell et al., manuscript in preparation) . We found that A 3 AR agonist treatment of both wild type and L90V A 3 AR transfected cells leads to a time-dependent increase in receptor/transporter complexes and an increase in SERT surface expression. Consistent with the enhanced cGMP signaling and 5-HT uptake stimulation of the L90V variant, cells transfected with the mutant receptor demonstrated a maintained stimulation of receptor/transporter complexes and SERT surface expression at a time when these measures had returned to basal levels in cells transfected with wild-type A 3 ARs. Because these effects are dependent on PKGI activation, we believe that the impact of the L90V variant on SERT arises from an elevated efficiency of receptor/G-protein coupling, possibly as a consequence of more limited receptor desensitization. Alhough further research is needed to fully elucidate this mechanism, they provide an example of how enhanced SERT activity need not arise from intrinsic changes in SERT structure such as we have found in subjects with ASD ) but can also be established through functional changes in the SERT regulatory network. 
